Niagen Bioscience (NAGE) Total Non-Current Liabilities (2011 - 2020)
Niagen Bioscience (NAGE) posted quarterly Total Non-Current Liabilities of $20.2 million for Q2 2020, down 30.73% year-over-year from $29.1 million in Q3 2019, and up 7.1% quarter-over-quarter from $18.8 million in Q1 2020.
Niagen Bioscience (NAGE) Total Non-Current Liabilities (2011 - 2020) Analysis & Trends
Niagen Bioscience (NAGE) has reported Total Non-Current Liabilities for 8 consecutive years, with $20.2 million the latest figure, recorded in Q2 2020.
- In Q2 2020, Total Non-Current Liabilities fell 30.73% year-over-year to $20.2 million; the TTM figure through Jun 2020 stood at $20.2 million (down 30.73% YoY), while the FY2019 annual figure was $19.6 million, up 32.84% from the prior year.
- Total Non-Current Liabilities climbed to $20.2 million in Q2 2020 per NAGE's latest filing, from $18.8 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $29.1 million in Q2 2019 and bottomed at $6.6 million in Q4 2016.
- Historically, Total Non-Current Liabilities has averaged $14.0 million across 5 years, with a median of $13.2 million in 2016.
- Annual changes were most pronounced in 2019 — Total Non-Current Liabilities surged 153.45% — and 2020, when it slumped 30.73%.
- Niagen Bioscience's Total Non-Current Liabilities stood at $9.4 million in 2016, then declined by 8.66% to $8.6 million in 2017, then soared by 72.33% to $14.8 million in 2018, then surged by 32.84% to $19.6 million in 2019, then advanced by 2.69% to $20.2 million in 2020.
- Business Quant data shows NAGE's Total Non-Current Liabilities at $20.2 million in Q2 2020, $18.8 million in Q1 2020, and $19.6 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Niagen Bioscience | 238.30 Mn | 171.56 Mn | 19.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 20.16 Mn |
| Mar 31, 2020 | 18.82 Mn |
| Dec 31, 2019 | 19.63 Mn |
| Sep 30, 2019 | 15.74 Mn |
| Jun 30, 2019 | 29.10 Mn |
| Mar 31, 2019 | 20.59 Mn |
| Dec 31, 2018 | 14.78 Mn |
| Sep 30, 2018 | 13.47 Mn |
| Jun 30, 2018 | 11.48 Mn |
| Mar 31, 2018 | 10.58 Mn |
| Dec 30, 2017 | 8.58 Mn |
| Sep 30, 2017 | 7.74 Mn |
| Jul 1, 2017 | 6.70 Mn |
| Apr 1, 2017 | 11.28 Mn |
| Dec 31, 2016 | 9.39 Mn |
| Oct 1, 2016 | 6.63 Mn |
| Jan 2, 2016 | 13.20 Mn |
| Mar 30, 2013 | 3.67 Mn |
| Dec 29, 2012 | 4.73 Mn |
| Sep 29, 2012 | 9.17 Mn |